AlbaCore Capital Group Announces Partnership Financing with MindMaze

LONDON/MUMBAI:
European credit investment firm AlbaCore Capital Group (“AlbaCore”),  announced that it has invested $125 million in Hinduja backed MindMaze (the “Company”), a global pioneer in the  digital neurotherapeutics market, delivering seamless digital assessments and therapeutics over the  full continuum of care in over twenty countries, serving thousands of patients suffering from  neurological conditions.

The Company currently collaborates with approximately ninety healthcare providers and has a product portfolio that has received three FDA clearances and four CE marks across eight clinical indications. MindMaze will use the proceeds to accelerate commercialization of, and enhance market access for, its approved and reimbursed neuro-rehabilitation platform as well as expanding its neuro- restorative portfolio.

David Allen, Managing Partner and Chief Investment Officer at AlbaCore Capital Group, commented:  “We are excited to partner with MindMaze and empower their critically important mission to change the face of brain health and recovery through advanced digital tools. At AlbaCore, we look to be a creative solutions provider with partnership at the core of everything we do. We believe that  MindMaze is positioned to dramatically improve care for millions of patients, and with this fresh capital  will be able to rapidly scale.”

Tej Tadi, PhD, MindMaze founder and CEO, added: “MindMaze is dedicated to improving the lives of patients around the world through the development of novel digital therapeutic products for the treatment of serious neurological conditions. We believe that the demands of a rapidly aging world population make our proprietary, proven solutions more critical now than ever before. We are thrilled to partner with AlbaCore as we build the leading universal platform for brain health and recovery. This financing will enable our dedicated team and partners to advance in our mission to help patients recover, learn and adapt through advanced neuroscience and digital therapeutics.”